During the 2021 TCT Meetings Digital Experience, the GvHD Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, What is new in haploidentical stem cell transplantation?
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
What is new in haploidentical stem cell transplantation?
What is new in haploidentical stem cell transplantation?
Nagler discusses the current status of haploidentical stem cell transplantation with a focus on post-transplant therapy with cyclophosphamide, which reduces chronic graft-versus-host disease (GvHD) and controls acute GvHD, providing earlier withdrawal of immunosuppression. He concludes by comparing haploidentical versus matched sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia and acute lymphoblastic leukemia.
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox